Challenges Facing Pharmaceutical R&D
Wednesday, September 10, 2014 from 4:00 PM to 6:00 PM (EDT)
New Haven, CT
San Francisco, California
London, United Kingdom
We are pleased to launch the Fall BIOHAVEN series with a presentation by Dr. John LaMattina, former Senior Vice President of Pfizer Inc. and former President of Pfizer Global Research and Development. In that role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS.
Dr. LaMattina will speak about the challenges facing pharmaceutical research and development, sharing his perspectives on the changing biopharmaceutical community. The conversation will target those who are interested in new medicines or partnership with pharmaceutical companies. There will be plenty of time for questions and discussion.
Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents. In addition, he is the author of "Drug Truths: Dispelling the Myths About Phama R&D" and "Devalued and Distrusted - Can the Pharmaceutical Industry Restore Its Broken Image?" He is also a contributor to Forbes.com.
He is currently a Senior Partner at PureTech Health and serves on the Board of Directors of Ligand Pharmaceuticals, Ziarco Pharmaceuticals, Zafgen, and the Scientific Advisory Board of Trevena Pharmaceuticals. Dr. LaMattina also serves on the Board of Trustees of Boston College, where he is the chair the Academic Affairs Committee.
When & Where
CURE is the bioscience cluster of Connecticut, a diverse network of small and large life and health care sciences companies, universities, scientists, educators, students, entrepreneurs, mentors, business experts, and investors. Together we cultivate entrepreneurship, build bioscience companies, and collaborate to ensure a sustainable, high-value bioscience and healthcare community that improves our quality of life and keeps the Connecticut economy strong.